A Diarrheal Prodrome and a Kidney Failing Faster Than It Should: Starting Eculizumab Before the Genetics Come Back
His illness started the way Shiga-toxin HUS is supposed to start — but it isn't behaving the way Shiga-toxin HUS is supposed to behave, and the test that would settle it takes weeks he may not have.
C.V., an 8-year-old boy, had four days of bloody diarrhea that his parents initially treated as a bad stomach bug before he became pale, lethargic, and then anuric over the past 36 hours, prompting the ICU admission he's in now. His labs confirm a thrombotic microangiopathy — schistocytes on smear, a hemoglobin of 6.2 g/dL, platelets at 24,000/µL, and a creatinine that has tripled from his estimated baseline — and the bloody-diarrhea prodrome is exactly the history that should point toward Shiga-toxin-producing E. coli as the cause, the most common trigger for HUS in children and typically a self-limited illness managed with supportive care and dialysis if needed, without any role for complement-blocking therapy.
What doesn't fit is the severity and the trajectory: STEC-HUS, even when it requires dialysis, does not usually also produce the focal seizure he had this morning, and his renal function has continued to worsen through 24 hours of aggressive supportive care rather than stabilizing the way most STEC-HUS courses do once fluids and dialysis are underway. Atypical HUS, driven by uncontrolled complement activation rather than Shiga toxin, produces exactly this picture — more severe, more likely to involve the central nervous system, and progressive rather than self-limited — and eculizumab, established in the prospective trials Legendre and colleagues reported, is life- and kidney-saving therapy for it, but the complement genetic testing that would confirm or exclude it takes weeks to return, and a stool culture for STEC is still pending as well, leaving the team to decide whether his actual clinical trajectory, not the history alone, already justifies treating him as atypical HUS before either test comes back.
His blood pressure, checked hourly since admission, has also crept upward despite no vasopressor support — 142/94 this morning against a normal baseline his pediatrician's records show from six months ago — a finding more in keeping with complement-mediated endothelial injury than with the more typically normotensive course of straightforward STEC-HUS, adding one more data point to a picture that keeps pointing the same direction.
In the PICU, 24 hours after admission, after the seizure
I'd start eculizumab now. His kidneys are getting worse, not stabilizing, despite everything supportive care can offer, and he seized this morning — that's not the typical STEC-HUS trajectory. If this is atypical HUS, every day we wait for a genetic panel that takes weeks is a day of preventable, permanent organ damage. Stopping eculizumab later if it turns out unnecessary is far easier than reversing kidney and brain injury that's already happened.
I'd want us to at least wait for the stool culture, which returns well before the genetic panel — a positive STEC result doesn't automatically rule out treatment, since severe STEC-HUS with neurologic involvement has been treated with eculizumab in its own right in case reports, but it changes how confidently we're committing him to ongoing complement blockade and its real infection risk without a firmer basis.
I'm not arguing to wait for the full genetic confirmation — just for the piece of information that's actually arriving soon and would meaningfully inform this.
I don't think either of you is actually wrong, and I'd reframe the decision rule rather than pick a side: what should drive this is his trajectory, not which label eventually turns out correct. Worsening renal function and a new seizure despite 24 hours of appropriate supportive care already meets a reasonable threshold for empiric treatment on severity alone, independent of the stool culture or genetics.
Start eculizumab now, with meningococcal vaccination and prophylactic antibiotics covering the gap before vaccine immunity develops. If the stool culture comes back positive for STEC in the next day or two, that doesn't automatically stop treatment — it becomes one more piece of information layered onto a decision that was already correctly made on how he's actually doing.
Agreed: eculizumab started today alongside meningococcal vaccination and prophylactic antibiotics, dialysis continued unchanged. All three voices agreed the decision rests on his trajectory, not on either pending test result.
It is documented as additional information, not treated as a reason to stop eculizumab given his severity, per the explicit agreement reached today.
It retrospectively validates today's empiric decision and guides long-term treatment planning; if it returns negative, the team reassesses duration of therapy at that point, not before.